FDA Grants Fast Track Designation to REGENXBIO’s RGX-111 Gene Therapy for Treatment of MPS I

ROCKVILLE, Md., June 12, 2018 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-111. RGX-111 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type I …

More From BioPortfolio on "FDA Grants Fast Track Designation to REGENXBIO’s RGX-111 Gene Therapy for Treatment of MPS I"